The Experts below are selected from a list of 5175 Experts worldwide ranked by ideXlab platform
Jerzy B Warchol - One of the best experts on this subject based on the ideXlab platform.
-
coexpression of human chorionic gonadotropin beta subunit and its receptor in nontrophoblastic gynecological Cancer
International Journal of Gynecological Cancer, 2008Co-Authors: Anna Jankowska, Miroslaw Andrusiewicz, Ewa Nowakmarkwitz, J Grabowski, Jerzy B WarcholAbstract:A considerable number of biochemical and physiologic studies evaluate the roles of gonadotropins in carcinogenesis. Latest reports show that human chorionic gonadotropin (hCG), and especially its beta subunit, are secreted by a variety of malignant tumors of different origin. However, the mechanism of hCG action and its role in tumor development is not known yet. This study, with the help of reverse transcription-polymerase chain reaction and immunohistochemistry, is an attempt to document the molecular presence of the hCGβ and luteinizing hormone/hCG receptor (LH/hCGR) in the ovarian, endometrial, and Uterine Cervix Cancer tissues. The LH/hCGR, coexpressed with hCGβ, may act as a potential mediator of hCG action in nontrophoblastic gynecological Cancers
-
reduction of human chorionic gonadotropin beta subunit expression by modified u1 snrna caused apoptosis in cervical Cancer cells
Molecular Cancer, 2008Co-Authors: Anna Jankowska, Anna Szczerba, Beata Burczynska, Miroslaw Andrusiewicz, Artur Jarmolowski, Ewa Nowakmarkwitz, Samuel I Gunderson, Jerzy B WarcholAbstract:Secretion of human chorionic gonadotropin, especially its beta subunit by malignant trophoblastic tumors and varieties of tumors of different origin is now well documented; however the role of hCG in tumorogenesis is still unknown. This study documents the molecular presence of human chorionic gonadotropin beta subunit in Uterine Cervix Cancer tissues and investigates a novel technique to reduce hCGβ levels based on expression of a modified U1 snRNA as a method to study the hormone's role in biology of human cervical Cancer cells cultured in vitro. The property of U1 snRNA to block the accumulation of specific RNA transcript when it binds to its donor sequence within the 3' terminal exon was used. The first 10 nucleotides of the human U1 snRNA gene, which normally binds to the 5'ss in pre-mRNA were replaced by a sequence complementary to a 10-nt segment in the terminal exon of the hCGβ mRNA. Three different 5' end-mutated U1 snRNA expression plasmids were tested, each targeting a different sequence in the hCGβ mRNA, and we found each one blocked the expression of hCGβ in HeLa cells, a Cervix carcinoma cell line, as shown by immunohistochemistry and qRT-PCR. Reduction of hCGβ levels resulted in a significantly increased apoptosis rate with almost 90% of cells transfected with modified anti-hCGβ U1 snRNAs showing morphological changes characteristic of the apoptotic process. These data suggest that human chorionic gonadotropin beta subunit may act as a tumor growth-stimulating factor.
Anna Jankowska - One of the best experts on this subject based on the ideXlab platform.
-
coexpression of human chorionic gonadotropin beta subunit and its receptor in nontrophoblastic gynecological Cancer
International Journal of Gynecological Cancer, 2008Co-Authors: Anna Jankowska, Miroslaw Andrusiewicz, Ewa Nowakmarkwitz, J Grabowski, Jerzy B WarcholAbstract:A considerable number of biochemical and physiologic studies evaluate the roles of gonadotropins in carcinogenesis. Latest reports show that human chorionic gonadotropin (hCG), and especially its beta subunit, are secreted by a variety of malignant tumors of different origin. However, the mechanism of hCG action and its role in tumor development is not known yet. This study, with the help of reverse transcription-polymerase chain reaction and immunohistochemistry, is an attempt to document the molecular presence of the hCGβ and luteinizing hormone/hCG receptor (LH/hCGR) in the ovarian, endometrial, and Uterine Cervix Cancer tissues. The LH/hCGR, coexpressed with hCGβ, may act as a potential mediator of hCG action in nontrophoblastic gynecological Cancers
-
reduction of human chorionic gonadotropin beta subunit expression by modified u1 snrna caused apoptosis in cervical Cancer cells
Molecular Cancer, 2008Co-Authors: Anna Jankowska, Anna Szczerba, Beata Burczynska, Miroslaw Andrusiewicz, Artur Jarmolowski, Ewa Nowakmarkwitz, Samuel I Gunderson, Jerzy B WarcholAbstract:Secretion of human chorionic gonadotropin, especially its beta subunit by malignant trophoblastic tumors and varieties of tumors of different origin is now well documented; however the role of hCG in tumorogenesis is still unknown. This study documents the molecular presence of human chorionic gonadotropin beta subunit in Uterine Cervix Cancer tissues and investigates a novel technique to reduce hCGβ levels based on expression of a modified U1 snRNA as a method to study the hormone's role in biology of human cervical Cancer cells cultured in vitro. The property of U1 snRNA to block the accumulation of specific RNA transcript when it binds to its donor sequence within the 3' terminal exon was used. The first 10 nucleotides of the human U1 snRNA gene, which normally binds to the 5'ss in pre-mRNA were replaced by a sequence complementary to a 10-nt segment in the terminal exon of the hCGβ mRNA. Three different 5' end-mutated U1 snRNA expression plasmids were tested, each targeting a different sequence in the hCGβ mRNA, and we found each one blocked the expression of hCGβ in HeLa cells, a Cervix carcinoma cell line, as shown by immunohistochemistry and qRT-PCR. Reduction of hCGβ levels resulted in a significantly increased apoptosis rate with almost 90% of cells transfected with modified anti-hCGβ U1 snRNAs showing morphological changes characteristic of the apoptotic process. These data suggest that human chorionic gonadotropin beta subunit may act as a tumor growth-stimulating factor.
Miroslaw Andrusiewicz - One of the best experts on this subject based on the ideXlab platform.
-
coexpression of human chorionic gonadotropin beta subunit and its receptor in nontrophoblastic gynecological Cancer
International Journal of Gynecological Cancer, 2008Co-Authors: Anna Jankowska, Miroslaw Andrusiewicz, Ewa Nowakmarkwitz, J Grabowski, Jerzy B WarcholAbstract:A considerable number of biochemical and physiologic studies evaluate the roles of gonadotropins in carcinogenesis. Latest reports show that human chorionic gonadotropin (hCG), and especially its beta subunit, are secreted by a variety of malignant tumors of different origin. However, the mechanism of hCG action and its role in tumor development is not known yet. This study, with the help of reverse transcription-polymerase chain reaction and immunohistochemistry, is an attempt to document the molecular presence of the hCGβ and luteinizing hormone/hCG receptor (LH/hCGR) in the ovarian, endometrial, and Uterine Cervix Cancer tissues. The LH/hCGR, coexpressed with hCGβ, may act as a potential mediator of hCG action in nontrophoblastic gynecological Cancers
-
reduction of human chorionic gonadotropin beta subunit expression by modified u1 snrna caused apoptosis in cervical Cancer cells
Molecular Cancer, 2008Co-Authors: Anna Jankowska, Anna Szczerba, Beata Burczynska, Miroslaw Andrusiewicz, Artur Jarmolowski, Ewa Nowakmarkwitz, Samuel I Gunderson, Jerzy B WarcholAbstract:Secretion of human chorionic gonadotropin, especially its beta subunit by malignant trophoblastic tumors and varieties of tumors of different origin is now well documented; however the role of hCG in tumorogenesis is still unknown. This study documents the molecular presence of human chorionic gonadotropin beta subunit in Uterine Cervix Cancer tissues and investigates a novel technique to reduce hCGβ levels based on expression of a modified U1 snRNA as a method to study the hormone's role in biology of human cervical Cancer cells cultured in vitro. The property of U1 snRNA to block the accumulation of specific RNA transcript when it binds to its donor sequence within the 3' terminal exon was used. The first 10 nucleotides of the human U1 snRNA gene, which normally binds to the 5'ss in pre-mRNA were replaced by a sequence complementary to a 10-nt segment in the terminal exon of the hCGβ mRNA. Three different 5' end-mutated U1 snRNA expression plasmids were tested, each targeting a different sequence in the hCGβ mRNA, and we found each one blocked the expression of hCGβ in HeLa cells, a Cervix carcinoma cell line, as shown by immunohistochemistry and qRT-PCR. Reduction of hCGβ levels resulted in a significantly increased apoptosis rate with almost 90% of cells transfected with modified anti-hCGβ U1 snRNAs showing morphological changes characteristic of the apoptotic process. These data suggest that human chorionic gonadotropin beta subunit may act as a tumor growth-stimulating factor.
Ewa Nowakmarkwitz - One of the best experts on this subject based on the ideXlab platform.
-
coexpression of human chorionic gonadotropin beta subunit and its receptor in nontrophoblastic gynecological Cancer
International Journal of Gynecological Cancer, 2008Co-Authors: Anna Jankowska, Miroslaw Andrusiewicz, Ewa Nowakmarkwitz, J Grabowski, Jerzy B WarcholAbstract:A considerable number of biochemical and physiologic studies evaluate the roles of gonadotropins in carcinogenesis. Latest reports show that human chorionic gonadotropin (hCG), and especially its beta subunit, are secreted by a variety of malignant tumors of different origin. However, the mechanism of hCG action and its role in tumor development is not known yet. This study, with the help of reverse transcription-polymerase chain reaction and immunohistochemistry, is an attempt to document the molecular presence of the hCGβ and luteinizing hormone/hCG receptor (LH/hCGR) in the ovarian, endometrial, and Uterine Cervix Cancer tissues. The LH/hCGR, coexpressed with hCGβ, may act as a potential mediator of hCG action in nontrophoblastic gynecological Cancers
-
reduction of human chorionic gonadotropin beta subunit expression by modified u1 snrna caused apoptosis in cervical Cancer cells
Molecular Cancer, 2008Co-Authors: Anna Jankowska, Anna Szczerba, Beata Burczynska, Miroslaw Andrusiewicz, Artur Jarmolowski, Ewa Nowakmarkwitz, Samuel I Gunderson, Jerzy B WarcholAbstract:Secretion of human chorionic gonadotropin, especially its beta subunit by malignant trophoblastic tumors and varieties of tumors of different origin is now well documented; however the role of hCG in tumorogenesis is still unknown. This study documents the molecular presence of human chorionic gonadotropin beta subunit in Uterine Cervix Cancer tissues and investigates a novel technique to reduce hCGβ levels based on expression of a modified U1 snRNA as a method to study the hormone's role in biology of human cervical Cancer cells cultured in vitro. The property of U1 snRNA to block the accumulation of specific RNA transcript when it binds to its donor sequence within the 3' terminal exon was used. The first 10 nucleotides of the human U1 snRNA gene, which normally binds to the 5'ss in pre-mRNA were replaced by a sequence complementary to a 10-nt segment in the terminal exon of the hCGβ mRNA. Three different 5' end-mutated U1 snRNA expression plasmids were tested, each targeting a different sequence in the hCGβ mRNA, and we found each one blocked the expression of hCGβ in HeLa cells, a Cervix carcinoma cell line, as shown by immunohistochemistry and qRT-PCR. Reduction of hCGβ levels resulted in a significantly increased apoptosis rate with almost 90% of cells transfected with modified anti-hCGβ U1 snRNAs showing morphological changes characteristic of the apoptotic process. These data suggest that human chorionic gonadotropin beta subunit may act as a tumor growth-stimulating factor.
Charles A. Kunos - One of the best experts on this subject based on the ideXlab platform.
-
Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Brachytherapy in Puerto Rico After Hurricane Maria
'Frontiers Media SA', 2019Co-Authors: Charles A. Kunos, Percy IvyAbstract:Evaluating the impact of natural disasters on Cancer patients is vital to the recovery of Cancer treatment services and infrastructure. In September 2017, Hurricane Maria demolished the gynecologic Cancer service in the United States territory of Puerto Rico and its outreach to the territory of the Virgin Islands of the United States. Patient access to brachytherapy for Uterine Cervix Cancer patients can be difficult to measure in the aftermath of a hurricane. The United States National Cancer Institute (NCI) surveyed gynecologic radiation medicine providers on the island to generate an independent perspective on gynecologic brachytherapy service recovery after the hurricane. Providers were asked about patient displacement, infrastructure loss, and reestablishment of Cancer treatment. Here, the NCI provides its perspective on recovery of these services as it relates to its pre-hurricane investment for staff in the NCI Community Oncology Research Program
-
Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Patient Accrual in Puerto Rico
Frontiers Media S.A., 2018Co-Authors: Charles A. Kunos, Holly A. Massett, Annette Galassi, Joan L. Walker, Marge J. Good, Luis Báez Díaz, Worta Mccaskill-stevensAbstract:Women in the U.S. Commonwealth of Puerto Rico (PR) have a higher age-adjusted incidence rate for Uterine Cervix Cancer than the U.S. mainland as well as substantial access and economic barriers to Cancer care. The National Cancer Institute (NCI) funds a Minority/Underserved NCI Community Oncology Research Program in PR (PRNCORP) as part of a national network of community-based health-care systems to conduct multisite Cancer clinical trials in diverse populations. Participation by the PRNCORP in NCI’s Uterine Cervix Cancer clinical trials, however, has remained limited. This study reports on the findings of an NCI site visit in PR to assess barriers impeding site activation and accrual to its sponsored gynecologic Cancer clinical trials. Qualitative, semi-structured individual, and group interviews were conducted at six PRNCORP-affiliated locations to ascertain: long-term trial accrual objectives; key stakeholders in PR that address Uterine Cervix Cancer care; key challenges or barriers to activating and to enrolling patients in NCI Uterine Cervix Cancer treatment trials; and resources, policies, or procedures in place or needed on the island to support NCI-sponsored clinical trials. An NCI-sponsored Uterine Cervix Cancer radiation–chemotherapy intervention clinical trial (NCT02466971), already activated on the island, served as a test case to identify relevant patient accrual and site barriers. The site visit identified five key barriers to accrual: (1) lack of central personnel to coordinate referrals for treatment plans, medical tests, and medical imaging across the island’s clinical trial access points; (2) patient insurance coverage; (3) lack of a coordinated brachytherapy schedule at San Juan-centric service providers; (4) limited credentialed radiotherapy machines island-wide; and (5) too few radiology medical physicists tasked to credential trial-specified positron emission tomography scanners island-wide. PR offers a unique opportunity to study overarching and tactical strategies for improving accrual to NCI-sponsored gynecologic Cancer clinical trials. Interview findings support adding and re-tasking personnel for coordinated trial-eligible patient referral, accrual, and treatment
-
a phase i ii evaluation of veliparib nsc 737664 topotecan and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the Uterine Cervix an nrg oncology gynecologic oncology group study
International Journal of Gynecological Cancer, 2015Co-Authors: Charles A. Kunos, Wei Deng, Dawn M Dawson, Jayanthi S Lea, Kristine M Zanotti, Heidi J Gray, David P Bender, Perry P Guaglianone, Jori S Carter, Kathleen N MooreAbstract:Purpose The aim of this study was to evaluate the tolerability and efficacy of poly(ADP-ribose) polymerase (PARP) inhibition by veliparib during cytotoxic topotecan administration with filgrastim or pegfilgrastim neutrophil support in women with persistent or recurrent Uterine Cervix Cancer. Experimental Design This phase I-II trial examined twice-daily oral veliparib (10 mg) given during once-daily intravenous topotecan (0.6 mg/m2) on days 1 to 5 of each treatment cycle. Cycles were repeated every 21 days until disease progression or until toxicity prohibited further therapy. Toxicity and objective response rate were primary endpoints. Results Twenty-seven women were enrolled. Frequently reported grade 3 or higher treatment-related toxicities were anemia (59%), thrombocytopenia (44%), leukopenia (22%), and neutropenia (19%). There were 2 partial responses (7% [90% confidence interval, 1%–22%]). Four patients had a disease progression date more than 6 months after the start of veliparib-topotecan therapy. Patients with low immunohistochemical expression (0–1+) of PARP-1 in their primary Uterine Cervix Cancer were more likely to have a longer progression-free interval (hazard ratio, 0.25; P = 0.02) and survival (hazard ratio, 0.12; P = 0.005) after veliparib-topotecan therapy. Conclusions Clinical activity of a veliparib-topotecan combination was minimal in women with persistent or recurrent Uterine Cervix Cancer. Women whose Uterine Cervix Cancers express PARP-1 at low levels may benefit preferentially from PARP inhibitors combined with cytotoxic therapies, suggesting further study of PARP expression as an integral triage biomarker.
